Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Products:Cardiovascular >> Angiogenesis >> Adhesion / ECM >> Matrix Metalloproteinases >> MMP
Overview
Product name
Anti-ADAMTS2 antibody - Carboxyterminal end
See all ADAMTS2 products (6) ...
Description
Rabbit polyclonal to ADAMTS2 - Carboxyterminal end
Specificity
Ab39197 recognizes the zymogen of ADAMTS2 at 140-130 kD in reduced Western blots, activated forms at 105-94 kD (major bands), and breakdown products at 50 kD and 34 kD in cell culture media and lysates.
Tested applications
Cross reactivity
Reacts with
Human
Immunogen
Synthetic peptide based on the carboxyterminal end of human ADAMTS2.
(Peptide available as ab41231.)
Properties
Form
Liquid
Storage instructions
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze / thaw cycles.
Storage buffer
Preservative: 0.05% Sodium Azide
Constituents: 50% Glycerol
Concentration
Concentration information loading...
Purity
Immunogen affinity purified
Clonality
Polyclonal
Isotype
IgG
Research areas
Cell Biology >> Proteolysis / Ubiquitin >> Proteolytic enzymes >> Metalloprotease >> ADAM TS
Cancer >> Invasion/microenvironment >> ECM >> Extracellular matrix >> ADAM protein family
Signal Transduction >> Cytoskeleton / ECM >> Extracellular Matrix >> ECM Enzymes >> MMP
Cardiovascular >> Angiogenesis >> Adhesion / ECM >> Matrix Metalloproteinases >> MMP
Applications
Show applications key
Our Abpromise guarantee covers the use of ab39197 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB
Application notes
WB: Use at an assay dependent dilution. Predicted molecular weight: 135 kDa. A recommended starting concentration for Western blots is 1:1,000 when using colorimetric substrates such as BCIP/NBT, and 1:5,000 for chemiluminescent substrates. Higher concentrations of antibody may be needed for samples from more distantly related species. EDTA/EGTA treatment of tissues or lysates is required to see latent zymogen. Dilution optimised using Chromogenic detection. Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
Target
Function
Cleaves the propeptides of type I and II collagen prior to fibril assembly. Does not act on type III collagen. May also play a role in development that is independent of its role in collagen biosynthesis.
Tissue specificity
Expressed at high level in skin, bone, tendon and aorta and at low levels in thymus and brain.
Involvement in disease
Defects in ADAMTS2 are the cause of Ehlers-Danlos syndrome type 7C (EDS7C) [MIM:225410]. EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS7C is marked by extremely fragile tissues, hyperextensible skin and easy bruising. Facial skin contains numerous folds, as in the cutis laxa syndrome.
Sequence similarities
Contains 1 disintegrin domain.
Contains 1 peptidase M12B domain.
Contains 1 PLAC domain.
Contains 4 TSP type-1 domains.
Domain
The spacer domain and the TSP type-1 domains are important for a tight interaction with the extracellular matrix.
Post-translational
modifications
The precursor is cleaved by a furin endopeptidase.
Cellular localization
Secreted > extracellular space > extracellular matrix.
Target information above from: UniProt accessionO95450
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Alternative names
- A disintegrin and metalloproteinase with thrombospondin motifs 2 antibody
- A disintegrin like and metalloprotease (reprolysin type) with thrombospondin type 1 motif 2 antibody
- ADAM metallopeptidase with thrombospondin type 1 motif 2 antibody
see all
Database links
- Entrez Gene: 9509 Human
- Omim: 604539 Human
- SwissProt: O95450 Human
- Unigene: 23871 Human
- Unigene: 591725 Human
Protocols
References for Anti-ADAMTS2 antibody - Carboxyterminal end (ab39197)
ab39197 has not yet been referenced specifically in any publications.
Publishing research using ab39197? Please let us know so that we can cite the reference in this datasheet
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"